Commitments and Contingencies - Additional Details (Details) ₪ in Millions, $ in Millions								2 Months Ended	6 Months Ended	12 Months Ended
	Feb. 13, 2018 product case defendant	Jul. 12, 2017 case	Jun. 28, 2017 USD ($) product defendant	Jun. 28, 2017 ILS (₪) product defendant	Mar. 29, 2017 USD ($) product	Mar. 29, 2017 ILS (₪) product	May 22, 2016 defendant	Nov. 30, 2011 application	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) case	Dec. 31, 2016 USD ($) case	Jun. 27, 2015 USD ($)	Feb. 16, 2018 product individual case	Jan. 26, 2018 product plaintiff case complaint	Jan. 16, 2018 product individual	Dec. 31, 2017 USD ($)	Dec. 31, 2017 $ / ₪	Dec. 31, 2017 manufacturer	Dec. 31, 2017 supermarket	Dec. 31, 2017 case	Dec. 31, 2017 dozens	Nov. 14, 2017 hearing	Nov. 01, 2017 individual	Jun. 21, 2017 product subclass individual
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2018 | $																$ 38.1
2019 | $																31.9
2020 | $																24.3
2021 | $																18.6
2022 | $																13.7
Thereafter | $																16.6
Loss Contingencies [Line Items]
Rent expense under all leases | $									$ 26.2	$ 50.9	$ 53.0	$ 39.2
Purchase obligation | $																$ 771.0
Number of dozens of other drugs | dozens																					2
Number of manufacturers | manufacturer																		31
Number of supermarket chains | supermarket																			3
Number of subclasses | subclass																								3
Number of former directors and officers | individual																								11
Number of generic prescription pharmaceuticals | product			6	6																				6
Number of individuals | individual																							3
Number of cases		3
Number of defendants | defendant							5
Number of drugs | product					2	2
Preliminary class damages			$ 760.0	₪ 2,700.0	$ 192.0	₪ 686.0
Foreign currency exchange rate, remeasurement										0.0028							0.0028
Number of current or former directors and officers | defendant			11	11
Number of cases dismissed		2								7
Number of applications filed | application								9
Number of applications dismissed | application								1
Number of applications consolidated | application								8
Number of applications | application								1
Number of hearings | hearing																						3
Losses and expenses per co-defendant, percentage										50.00%
Number of claims settled											1
Number of claims dismissed with prejudice											2
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product	6												6	6	6
Number of individuals | individual													3		3
Number of plaintiff groups | plaintiff														2
Number of complaints | complaint														2
Number of cases not securities class actions														2
Number of cases	4													1
Number of defendants | defendant	2
Number of overlapped cases	2
Number of opt out cases	4												5
ISRAEL
Loss Contingencies [Line Items]
Pending cases																				3
Number of cases dismissed										2
Loss Contingency, Number Of Cases Stayed										1